| Company type | Privately held company |
|---|---|
| Industry | research and development in biotechnology
 |
| Founded | Marseille, France (1999) |
| Founder |
|
| Defunct | 2015 |
| Fate | Acquired by Hoffmann-La Roche |
| Headquarters | France
|
Trophos was a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan neurodegenerative diseases and more prevalent disorders.[ citation needed]
Trophos was founded in 1999 in Marseille by three scientists: Christopher Henderson, Olivier Pourquie and Jean-Louis Kraus, and two entrepreneurs: Antoine Beret and Michel Delaage. Trophos' lead compound was olesoxime (TRO19622), [1] [2] a mitochondrial targeted compound developed to treat neurodegenerative diseases. [3] [4]
In January 2015, Hoffmann-La Roche announced its intention to buy Trophos for €120,000,000 upfront and up to €350,000,000 in milestone performance payments. [5] [6] The deal was completed shortly afterwards.
References
- ^ Bordet, T.; Buisson, B.; Michaud, M.; Drouot, C.; Galea, P.; Delaage, P.; Akentieva, N. P.; Evers, A. S.; Covey, D. F.; Ostuni, M. A.; Lacapere, J.-J.; Massaad, C.; Schumacher, M.; Steidl, E.-M.; Maux, D.; Delaage, M.; Henderson, C. E.; Pruss, R. M. (2007). "Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis". Journal of Pharmacology and Experimental Therapeutics. 322 (2): 709–720. doi: 10.1124/jpet.107.123000. PMID 17496168. S2CID 17271734.
- ^ "olesoxime". UKMi New Drugs Online Database. Retrieved 2 January 2016.
- ^ "Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy". ClinicalTrials.gov. 5 February 2010. Retrieved 3 October 2010.
- ^ "Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)". ClinicalTrials.gov. May 2010. Retrieved 3 October 2010.
- ^ Franklin, Joshua (16 January 2015). "Roche buys France's Trophos to expand in neuromuscular disease". Reuters. Retrieved 30 December 2015.
- ^ Staff (15 February 2015). "Roche to Buy Trophos for Up-to-$543M". Genetic Engineering & Biotechnology News (paper). Vol. 35, no. 4. p. 6.
Further reading
- Rovini, Amandine; Carré, Manon; Bordet, Thierry; Pruss, Rebecca M.; Braguer, Diane (2010). "Olesoxime prevents microtubule-targeting drug neurotoxicity: Selective preservation of EB comets in differentiated neuronal cells". Biochemical Pharmacology. 80 (6): 884–894. doi: 10.1016/j.bcp.2010.04.018. PMID 20417191.
- Xiao, Wen Hua; Zheng, Felix Y.; Bennett, Gary J.; Bordet, Thierry; Pruss, Rebecca M. (2009). "Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel". Pain. 147 (1–3): 202–9. doi: 10.1016/j.pain.2009.09.006. PMC 2787910. PMID 19833436.
- Bordet, T.; Buisson, B.; Michaud, M.; Abitbol, J.-L.; Marchand, F.; Grist, J.; Andriambeloson, E.; Malcangio, M.; Pruss, R. M. (2008). "Specific Antinociceptive Activity of Cholest-4-en-3-one, Oxime (TRO19622) in Experimental Models of Painful Diabetic and Chemotherapy-Induced Neuropathy". Journal of Pharmacology and Experimental Therapeutics. 326 (2): 623–632. doi: 10.1124/jpet.108.139410. PMID 18492948. S2CID 33726393.
| Company type | Privately held company |
|---|---|
| Industry | research and development in biotechnology
|
| Founded | Marseille, France (1999) |
| Founder |
|
| Defunct | 2015 |
| Fate | Acquired by Hoffmann-La Roche |
| Headquarters | France
|
Trophos was a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan neurodegenerative diseases and more prevalent disorders.[ citation needed]
Trophos was founded in 1999 in Marseille by three scientists: Christopher Henderson, Olivier Pourquie and Jean-Louis Kraus, and two entrepreneurs: Antoine Beret and Michel Delaage. Trophos' lead compound was olesoxime (TRO19622), [1] [2] a mitochondrial targeted compound developed to treat neurodegenerative diseases. [3] [4]
In January 2015, Hoffmann-La Roche announced its intention to buy Trophos for €120,000,000 upfront and up to €350,000,000 in milestone performance payments. [5] [6] The deal was completed shortly afterwards.
References
- ^ Bordet, T.; Buisson, B.; Michaud, M.; Drouot, C.; Galea, P.; Delaage, P.; Akentieva, N. P.; Evers, A. S.; Covey, D. F.; Ostuni, M. A.; Lacapere, J.-J.; Massaad, C.; Schumacher, M.; Steidl, E.-M.; Maux, D.; Delaage, M.; Henderson, C. E.; Pruss, R. M. (2007). "Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis". Journal of Pharmacology and Experimental Therapeutics. 322 (2): 709–720. doi: 10.1124/jpet.107.123000. PMID 17496168. S2CID 17271734.
- ^ "olesoxime". UKMi New Drugs Online Database. Retrieved 2 January 2016.
- ^ "Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy". ClinicalTrials.gov. 5 February 2010. Retrieved 3 October 2010.
- ^ "Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)". ClinicalTrials.gov. May 2010. Retrieved 3 October 2010.
- ^ Franklin, Joshua (16 January 2015). "Roche buys France's Trophos to expand in neuromuscular disease". Reuters. Retrieved 30 December 2015.
- ^ Staff (15 February 2015). "Roche to Buy Trophos for Up-to-$543M". Genetic Engineering & Biotechnology News (paper). Vol. 35, no. 4. p. 6.
Further reading
- Rovini, Amandine; Carré, Manon; Bordet, Thierry; Pruss, Rebecca M.; Braguer, Diane (2010). "Olesoxime prevents microtubule-targeting drug neurotoxicity: Selective preservation of EB comets in differentiated neuronal cells". Biochemical Pharmacology. 80 (6): 884–894. doi: 10.1016/j.bcp.2010.04.018. PMID 20417191.
- Xiao, Wen Hua; Zheng, Felix Y.; Bennett, Gary J.; Bordet, Thierry; Pruss, Rebecca M. (2009). "Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel". Pain. 147 (1–3): 202–9. doi: 10.1016/j.pain.2009.09.006. PMC 2787910. PMID 19833436.
- Bordet, T.; Buisson, B.; Michaud, M.; Abitbol, J.-L.; Marchand, F.; Grist, J.; Andriambeloson, E.; Malcangio, M.; Pruss, R. M. (2008). "Specific Antinociceptive Activity of Cholest-4-en-3-one, Oxime (TRO19622) in Experimental Models of Painful Diabetic and Chemotherapy-Induced Neuropathy". Journal of Pharmacology and Experimental Therapeutics. 326 (2): 623–632. doi: 10.1124/jpet.108.139410. PMID 18492948. S2CID 33726393.